NeoStrata HQ Plus Lightening Gel
Testo originale in francese.
Prodotto naturale per la salute autorizzato in Canada
L’analisi delle dosi orali non si applica senza una via esclusivamente orale accertata.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte |
|---|---|
| Hydroquinone | 4 % (p/p) |
Ingredienti non medicinali
Ammonia Solution, Strong NF, Chlorure de benzalkonium, Ethoxydiglycol, Eau, Hydroxyethyl Cellulose, Métabisulfite de sodium, Éthanol, Gluconolactone, Acide glycolique, propylèneglycol
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
| Adultes | minimum : 20 ans | Non précisée | minimum : 1 Tous les jours ; maximum : 2 Tous les jours |
Usi autorizzati in Canada
Lightens age spots and hyperpigmentation.
Testo originale in francese.
Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Précautions et mises en garde : To be used on the advice of a physician. For external use only. Use only as directed. Do not apply over sunburn or irritated skin. Do not apply over sunburn or irritated skin. Avoid contact with eyes, mucous membranes and broken or irritated skin. In case of contact, rinse thoroughly with water. Test for sensitivity. Apply only to small skin surface area. Discontinue use and consult a physician in case of skin reactions or a blue-black darkening of the skin. A mild transient stinging or minor redness may occur in people with sensitive skin. To test for sensitivity, before treatment, apply to area of approximately 1 cm2 of unbroken skin on the inside of the arm. If no irritations occurs within 24 hours, begin treatment for up to 12 weeks. Discontinue use in case of irritation, rash, excessive inflammatory response or if a gradual blue-black darkening of the skin (exogenous ochronosis) occurs. Minor redness is acceptable, but when there is an excessive irritation, a rash or other reaction, further treatment is not advised. Severe itching or reddening may occur, in which case the product should be discontinued and the physician notified immediately. This product contains glycolic acid, an alpha-hydroxy acid (AHA), which may increase skin's sensitivity to the sun and particularly the possibility of sunburn. Limit sun exposure and apply a sunburn protectant while using this product and for a week afterwards. The safety of topical hydroquinone use during pregnancy or for children 12 years or less has not been established. Do not use this product if you have used it or any of its ingredients before and skin sensitivity or irritation has occurred. Do not use this product if you are nursing, pregnant or if you intended to become pregnant within 3 months of use. If you have a family history or, have or have had or are at risk of developing cancer, do not use. Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of the insert before prescribing or dispensing this product. Close patient supervision is recommended. A bitter taste and anesthetic effect may occur if applied to the lips. Sunscreen use is essential aspect of hydroquinone therapy because even minimal sunlight exposure may cause skin re-darkening. Treatment should be limited to relatively small areas of the body at one time. Keep out of reach of children. Not for use on children under 12 years of age. In case of accidental ingestion, seek medical assistance or contact a Poison Control Center immediately. Note: Slight darkening of the product is normal when exposed to air and does not affect its potency. When this happens, extract a tiny amount of product, clean with a cotton swab and discard prior to use. If the entire content becomes brown, discontinue use and consult a physician. Store at room temperature.
Testo originale in francese.
Scheda del prodotto
- Titolare
- Opella Canada Inc.
- NPN o DIN-HM
- 02245719
- Stato
- Licenza non attiva
- Data della licenza
- 17 dicembre 2007
- Data di revisione
- 21 febbraio 2014
- Forma
- Gel
- Via di somministrazione
- Topique
- Tipo di domanda
- DIN de transition
Fonte
Scheda ufficiale Health Canada, licenza 02245719
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Testo originale in inglese.
Testo originale in francese.
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).
Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.